Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso Sells 36,838 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total transaction of $172,033.46. Following the completion of the sale, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at $500,096.29. The trade was a 25.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The stock was sold at an average price of $8.19, for a total value of $24,668.28.

Precision BioSciences Price Performance

Shares of NASDAQ:DTIL opened at $4.97 on Thursday. The firm has a market capitalization of $38.12 million, a PE ratio of 82.85 and a beta of 1.51. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The company has a 50-day moving average price of $5.62 and a two-hundred day moving average price of $8.04. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $19.43.

Analyst Upgrades and Downgrades

DTIL has been the subject of a number of research analyst reports. BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a research note on Friday, January 10th.

Hedge Funds Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC raised its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.